Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Cel-Sci

Executive Summary

Cel-Sci: Institutional investors purchase $5 mil. in convertible series B preferred stock, Alexandria, Va.-based Cel-Sci reports Aug. 19. The preferred stock is convertible prior to August 1998. "The financing is set up" to minimize the impact of "the recent decrease in the company's stock price," Cel-Sci says. "Conversion prices will depend mostly on the future stock price." Cel-Sci estimates its $10 mil. in total funding will sustain operations for two years...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS028743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel